FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011646162> ?p ?o ?g. }

• W2011646162 endingPage "97" @default.
• W2011646162 startingPage "88" @default.
• W2011646162 abstract "Abstract Objective To investigate the polymorphisms in the promoter region of the B lymphocyte stimulator (BLyS) gene as markers of response to rituximab (RTX) in rheumatoid arthritis (RA). Methods The study was first conducted in 152 Italian RA patients and then replicated in an additional 117 RA patients (73 Italian, 44 British). The European League Against Rheumatism response criteria were used to evaluate the response rate at months 4 and 6 after the first cycle of RTX, by means of the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; patients were classified according to the best response shown between months 4 and 6. BLyS promoter polymorphisms were analyzed by polymerase chain reaction followed by the analysis of the restriction fragments, BLyS promoter haplotypes were analyzed using the expectation‐maximization algorithm, and BLyS serum levels were analyzed using enzyme‐linked immunosorbent assay. Odds ratios (ORs) were calculated with 95% confidence intervals (95% CIs). Results The TTTT BLyS promoter haplotype appeared to be significantly associated with response to RTX only in the subset of seropositive patients (those positive for rheumatoid factor and/or anti–cyclic citrullinated peptide). The replication study confirmed that this association was limited to seropositive RA patients in whom treatment with anti–tumor necrosis factor (anti‐TNF) agents had previously failed. In the whole series of seropositive patients in whom anti‐TNF agents had previously failed, patients carrying the TTTT BLyS promoter haplotype were more prevalent in good responders (18 of 43 [41.9%]) than in moderate responders (20 of 83 [24.1%]) or in nonresponders (1 of 21 [4.8%]) (for good responders versus nonresponders, OR 14.4 [95% CI 1.77–117.39], P = 0.0028). Furthermore, multivariate analysis selected the TTTT BLyS promoter haplotype as an independent marker of good response to RTX (for good responders versus nonresponders, OR 16.2 [95% CI 1.7–152.5], P = 0.01; for good responders versus moderate responders and nonresponders combined, OR 3.1 [95% CI 1.2–7.8], P = 0.02). The relationship between BLyS polymorphisms and BLyS serum levels remained unclear. Conclusion BLyS promoter genotyping may be suitable for identifying seropositive RA patients who may have a good response to RTX after anti‐TNF agents have failed." @default.
• W2011646162 created "2016-06-24" @default.
• W2011646162 creator A5006667947 @default.
• W2011646162 creator A5008092012 @default.
• W2011646162 creator A5010370846 @default.
• W2011646162 creator A5010984168 @default.
• W2011646162 creator A5012606835 @default.
• W2011646162 creator A5012750592 @default.
• W2011646162 creator A5013492063 @default.
• W2011646162 creator A5017440327 @default.
• W2011646162 creator A5022974460 @default.
• W2011646162 creator A5024114415 @default.
• W2011646162 creator A5026614224 @default.
• W2011646162 creator A5026797171 @default.
• W2011646162 creator A5032713218 @default.
• W2011646162 creator A5033972163 @default.
• W2011646162 creator A5034821482 @default.
• W2011646162 creator A5037295594 @default.
• W2011646162 creator A5043423755 @default.
• W2011646162 creator A5044733599 @default.
• W2011646162 creator A5048428887 @default.
• W2011646162 creator A5050227412 @default.
• W2011646162 creator A5053288231 @default.
• W2011646162 creator A5053725389 @default.
• W2011646162 creator A5053922189 @default.
• W2011646162 creator A5057509502 @default.
• W2011646162 creator A5057903643 @default.
• W2011646162 creator A5067014681 @default.
• W2011646162 creator A5071162889 @default.
• W2011646162 creator A5074722507 @default.
• W2011646162 creator A5077780247 @default.
• W2011646162 creator A5080993054 @default.
• W2011646162 date "2012-12-27" @default.
• W2011646162 modified "2023-10-12" @default.
• W2011646162 title "The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers" @default.
• W2011646162 cites W1518008196 @default.
• W2011646162 cites W1524209515 @default.
• W2011646162 cites W1528172769 @default.
• W2011646162 cites W1675831178 @default.
• W2011646162 cites W183561440 @default.
• W2011646162 cites W1847239991 @default.
• W2011646162 cites W1969467075 @default.
• W2011646162 cites W1971802929 @default.
• W2011646162 cites W1980521490 @default.
• W2011646162 cites W1985004174 @default.
• W2011646162 cites W1985380203 @default.
• W2011646162 cites W1988476615 @default.
• W2011646162 cites W1993803736 @default.
• W2011646162 cites W1998843795 @default.
• W2011646162 cites W2000905503 @default.
• W2011646162 cites W2014086244 @default.
• W2011646162 cites W2024644107 @default.
• W2011646162 cites W2040126057 @default.
• W2011646162 cites W2041088430 @default.
• W2011646162 cites W2055338105 @default.
• W2011646162 cites W2059125686 @default.
• W2011646162 cites W2062189802 @default.
• W2011646162 cites W2086839032 @default.
• W2011646162 cites W2097583687 @default.
• W2011646162 cites W2108787411 @default.
• W2011646162 cites W2110177517 @default.
• W2011646162 cites W2118994799 @default.
• W2011646162 cites W2121508861 @default.
• W2011646162 cites W2124026444 @default.
• W2011646162 cites W2126326247 @default.
• W2011646162 cites W2126687587 @default.
• W2011646162 cites W2128528140 @default.
• W2011646162 cites W2135856630 @default.
• W2011646162 cites W2141468693 @default.
• W2011646162 cites W2142165059 @default.
• W2011646162 cites W2148675722 @default.
• W2011646162 cites W2152348310 @default.
• W2011646162 cites W2152676410 @default.
• W2011646162 cites W2168792642 @default.
• W2011646162 cites W60759546 @default.
• W2011646162 cites W85071208 @default.
• W2011646162 doi "https://doi.org/10.1002/art.37707" @default.
• W2011646162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23001900" @default.
• W2011646162 hasPublicationYear "2012" @default.
• W2011646162 type Work @default.
• W2011646162 sameAs 2011646162 @default.
• W2011646162 citedByCount "25" @default.
• W2011646162 countsByYear W20116461622013 @default.
• W2011646162 countsByYear W20116461622014 @default.
• W2011646162 countsByYear W20116461622015 @default.
• W2011646162 countsByYear W20116461622016 @default.
• W2011646162 countsByYear W20116461622017 @default.
• W2011646162 countsByYear W20116461622019 @default.
• W2011646162 countsByYear W20116461622020 @default.
• W2011646162 countsByYear W20116461622021 @default.
• W2011646162 countsByYear W20116461622022 @default.
• W2011646162 crossrefType "journal-article" @default.
• W2011646162 hasAuthorship W2011646162A5006667947 @default.
• W2011646162 hasAuthorship W2011646162A5008092012 @default.
• W2011646162 hasAuthorship W2011646162A5010370846 @default.
• W2011646162 hasAuthorship W2011646162A5010984168 @default.
• W2011646162 hasAuthorship W2011646162A5012606835 @default.
• W2011646162 hasAuthorship W2011646162A5012750592 @default.

• next